Home / People / Frances Denney
Frances Denney

Frances Denney

European Patent Attorney

T +44 20 7067 3261
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Frances is a European Patent Attorney in the IP department. She mainly works in the Life Sciences space, drafting and prosecuting patent applications before the UK and European Patent Offices, as well as working on opposition and appeal cases. Frances also has experience assisting on patent litigations, corporate due diligence, and freedom-to-operate matters. She works on a variety of technologies, including CRISPR, RNAi, biomarkers, IVF and medical devices to name a few. She is also comfortable in more chemical and mechanical areas including ‘Markush formula’ inventions, and oil/gas purification methods and apparatus.

Prior to joining CMS, Frances worked for a start-up biotech company, helping to develop their business plan and R&D pipelines.

more less


  • 2016 – Certificate in IP Law – Queen Mary University of London, London
  • 2014 – MSc Drug Discovery and Pharma Management – UCL, London
  • 2013 – BSc Biochemistry – UCL, London
more less


Show only
19 September 2019
AI & pa­tient com­pli­ance
This art­icle looks at tech­no­logy in the area of pa­tient com­pli­ance, an area where AI is hav­ing a huge im­pact on the life sci­ences in­dustry. Tech­no­lo­gies fa­cil­it­at­ing pa­tient com­pli­ance raise a host of in­tel­lec­tu­al prop­erty con­sid­er­a­tions in Europe.
25 June 2020
Su­preme Court De­cision - Re­gen­er­on v Kymab [2020] UK­SC 27
Who knew a mouse could cause so much trouble? The Su­preme Court handed down its judg­ment in the case of Re­gen­er­on v Kymab this week, rul­ing that the as­ser­ted claims of Re­gen­er­on’s European pat­ent EP1360287...
19 May 2020
Not Pat­entable – The end of the line for plants and an­im­als pro­duced by...
The highest ju­di­cial au­thor­ity at the EPO is­sued their opin­ion late last week in the con­tro­ver­sial G3/19 (Pep­per) case. Con­trary to pre­vi­ous de­cisions in G2/12 and G2/13 (To­mato/Broc­coli), the En­larged...
31 January 2020
A Short Guide: Pri­or­ity En­ti­tle­ment at the EPO
Art­icle 87 EPC Pri­or­ity right (1) Any per­son who has duly filed, in or for (a) any State party to the Par­is Con­ven­tion for the Pro­tec­tion of In­dus­tri­al Prop­erty or (b) any Mem­ber of the World Trade...
20 December 2019
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
17 December 2019
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....
13 September 2019
SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
30 May 2019
EPO's strict ap­proach to de­cid­ing if a com­pos­i­tion can be­ne­fit from med­ic­al...
The EPO Tech­nic­al Board of Ap­peal (TBA) re­viewed the law around nov­elty of use, and de­term­ined that in the case of Car­di­oPoly­mer, Inc.'s European pat­ent ap­plic­a­tion (EP07837908.8), the claimed chem­ic­al...